Equities analysts predict that Theravance Biopharma Inc (NASDAQ:TBPH) will report sales of $6.86 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Theravance Biopharma’s earnings, with the lowest sales estimate coming in at $4.60 million and the highest estimate coming in at $9.12 million. Theravance Biopharma posted sales of $3.09 million in the same quarter last year, which suggests a positive year over year growth rate of 122%. The firm is expected to report its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Theravance Biopharma will report full-year sales of $6.86 million for the current fiscal year, with estimates ranging from $42.87 million to $67.90 million. For the next year, analysts forecast that the business will post sales of $85.30 million per share, with estimates ranging from $64.91 million to $105.70 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Theravance Biopharma.
A number of brokerages have recently issued reports on TBPH. ValuEngine downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Needham & Company LLC restated a “buy” rating on shares of Theravance Biopharma in a research report on Tuesday, December 5th. BidaskClub downgraded shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 3rd. Finally, Leerink Swann boosted their price target on shares of Theravance Biopharma from $45.00 to $48.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $42.00.
Hedge funds and other institutional investors have recently modified their holdings of the company. Moneta Group Investment Advisors LLC acquired a new position in shares of Theravance Biopharma during the 3rd quarter valued at $299,000. SG Americas Securities LLC lifted its position in shares of Theravance Biopharma by 52.8% during the 3rd quarter. SG Americas Securities LLC now owns 9,061 shares of the biopharmaceutical company’s stock valued at $310,000 after acquiring an additional 3,130 shares during the period. Landscape Capital Management L.L.C. acquired a new position in shares of Theravance Biopharma during the 4th quarter valued at $313,000. Parametric Portfolio Associates LLC lifted its position in shares of Theravance Biopharma by 1.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 14,307 shares of the biopharmaceutical company’s stock valued at $570,000 after acquiring an additional 217 shares during the period. Finally, Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma during the 4th quarter valued at $416,000. Hedge funds and other institutional investors own 86.62% of the company’s stock.
Shares of TBPH stock traded down $0.13 during midday trading on Thursday, hitting $26.47. 100,668 shares of the stock were exchanged, compared to its average volume of 236,629. The firm has a market cap of $1,420.97, a P/E ratio of -4.86 and a beta of 1.78. Theravance Biopharma has a 1 year low of $22.90 and a 1 year high of $43.44. The company has a quick ratio of 5.79, a current ratio of 6.05 and a debt-to-equity ratio of 1.94.
COPYRIGHT VIOLATION WARNING: “Theravance Biopharma Inc (TBPH) Expected to Post Quarterly Sales of $6.86 Million” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/03/20/theravance-biopharma-inc-tbph-expected-to-post-quarterly-sales-of-6-86-million.html.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.